Literature DB >> 21906844

Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae.

Abraham Borer1, Lisa Saidel-Odes, Seada Eskira, Ronit Nativ, Klaris Riesenberg, Ilana Livshiz-Riven, Francisc Schlaeffer, Michael Sherf, Nejama Peled.   

Abstract

BACKGROUND: This study examined predictors of carbapenem-resistant Klebsiella pneumoniae (CRKP) colonization and risk factors for the development of CRKP infection in patients initially only colonized with CRKP.
METHODS: A total of 464 patients with CRKP rectal colonization (CRKP-RC) were identified. Two case-control studies were performed, one comparing risk factors for CRKP-RC in patients who did not develop CRKP infection (CRKP-IN) versus patients without CRKP-RC and CRKP-IN, and the other comparing CRKP-RC patients who did not develop CRKP-IN with those who did.
RESULTS: Forty-two of the 464 colonized patients developed CRKP-IN. Multivariate analysis identified the following predictors for CRKP-RC: antibiotic therapy (odds ratio [OR], 5.76; P ≤ .0001), aminopenicillin therapy (OR, 7.753; P = .004), bedridden (OR, 3.09; P = .021), and nursing home residency (OR, 3.09; P = .013). Risk factors for CRKP-IN in initially CRKP-RC-positive patients were previous invasive procedure (OR, 5.737; P = .021), diabetes mellitus (OR, 4.362; P = .017), solid tumor (OR, 3.422; P = .025), tracheostomy (OR, 4.978; P = .042), urinary catheter insertion (OR, 4.696; P = .037), and antipseudomonal penicillin (OR, 23.09; P ≤ .0001).
CONCLUSIONS: We suggest that in patients with CRKP-RC, a strategy for preventing CRKP-IN might include limiting antipseudomonal penicillin and carbapenem use and preventing infections by closely following compliance with infection control bundles.
Copyright © 2012 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906844     DOI: 10.1016/j.ajic.2011.05.022

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  65 in total

1.  KPC-producing, multidrug-resistant Klebsiella pneumoniae sequence type 258 as a typical opportunistic pathogen.

Authors:  L S Tzouvelekis; V Miriagou; S D Kotsakis; K Spyridopoulou; E Athanasiou; E Karagouni; E Tzelepi; G L Daikos
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

2.  Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study.

Authors:  D R Giacobbe; V Del Bono; P Bruzzi; S Corcione; M Giannella; A Marchese; L Magnasco; A E Maraolo; N Pagani; C Saffioti; S Ambretti; C S Cardellino; E Coppo; F G De Rosa; P Viale; C Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-12-01       Impact factor: 3.267

3.  Epidemiology and clinical outcomes of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria.

Authors:  Zubair A Qureshi; Alveena Syed; Lloyd G Clarke; Yohei Doi; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

4.  Characteristics and management of Enterobacteriaceae harboring IMP-4 or IMP-8 carbapenemase in a tertiary hospital.

Authors:  Feng Pang; Xiu-Qin Jia; Zhen-Zhu Song; Yan-Hua Li; Bin Wang; Qi-Gang Zhao; Chuan-Xin Wang; Yi Zhang; Le-Xin Wang
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

5.  Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: relevance of concomitant systemic antibiotic therapy.

Authors:  Carlo Tascini; Francesco Sbrana; Sarah Flammini; Enrico Tagliaferri; Fabio Arena; Alessandro Leonildi; Ilaria Ciullo; Francesco Amadori; Antonello Di Paolo; Andrea Ripoli; Russell Lewis; Gian Maria Rossolini; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

6.  Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States.

Authors:  S M Bartsch; J A McKinnell; L E Mueller; L G Miller; S K Gohil; S S Huang; B Y Lee
Journal:  Clin Microbiol Infect       Date:  2016-09-15       Impact factor: 8.067

7.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 8.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  The Economic Value of the Centers for Disease Control and Prevention Carbapenem-Resistant Enterobacteriaceae Toolkit.

Authors:  Sarah M Bartsch; Susan S Huang; James A McKinnell; Kim F Wong; Leslie E Mueller; Loren G Miller; Bruce Y Lee
Journal:  Infect Control Hosp Epidemiol       Date:  2018-03-19       Impact factor: 3.254

10.  Molecular epidemiology of colonizing and disease-causing Klebsiella pneumoniae in paediatric patients.

Authors:  Malaika L Little; Xuan Qin; Danielle M Zerr; Scott J Weissman
Journal:  J Med Microbiol       Date:  2014-01-25       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.